The U.S. District Court for the Eastern District of Texas March 31 that the Food and Drug Administration does not have the authority to regulate laboratory-developed tests.

The FDA  issued a final rule that would have phased out its general enforcement discretion approach for most lab-developed tests over four years. The phase-out deadlines set in the final rule are no longer in effect.

The AHA previously expressed concerns about the proposed rule and  the FDA not to apply the rule to hospital and health system lab-developed tests.

鈥淭his ruling ensures that hospital-based labs are able to continue to develop innovative and high-quality tests that provide physicians with important clinical information to help diagnose and treat patients,鈥 said Jason Kleinman, AHA director of federal relations. 鈥淭he LDT final rule would have stifled medical innovation and dramatically increased regulatory burden and costs for both hospitals and the federal government.鈥

Related News Articles

Headline
The Food and Drug Administration April 29 issued a final rule that would phase out its general enforcement discretion approach for most laboratory developed鈥
Headline
The Food and Drug Administration鈥檚 proposal to regulate laboratory developed tests would undermine innovation and reduce access to effective and appropriate鈥
Headline
The Food and Drug Administration鈥檚 proposal to regulate laboratory developed tests would undermine innovation and reduce access to effective and appropriate鈥
Headline
AHA Dec. 1 urged the Food and Drug Administration not to apply its device regulations to hospital and health system laboratory developed tests. Commenting鈥